Epigenetics & Epiproteomics: A New Therapeutic Frontier
Rewriting the Rules of Disease Intervention
The future of medicine reaches beyond genome. While DNA provides the genetic blueprint, it’s epigenetics and epiproteomics that determine how that blueprint is interpreted, regulated and translated into cellular action. These dynamic biological systems control gene expression and protein behavior—without altering the underlying genetic code.
What is Epigenetics?
Epigenetics refers to reversible chemical modifications—such as DNA methylation and histone acetylation—that regulate which genes are turned on or off. These changes are essential for normal development and cell function, but when dysregulated, can contribute to the onset and progression of disease.
What is Epiproteonics?
Epiproteomics centers on post-translational modifications (PTMs) — the chemical changes made to proteins after synthesis. These modifications fine–tune protein function, stability, localization, and interaction, playing a key role in how cells respond to environmental and internal signals.
From Molecular Dysregulation to Disease
Disruptions in epigenetic and epiproteomic processes are implicated in a wide range of complex diseases:
- Cancer – through epigenetic silencing of tumor suppressors or aberrant protein signaling.
Obesity — linked to metabolic inflammation and impaired leptin signaling, leading to dysregulated energy homeostasis and weight control.
- Neurodegenerative disorders – involving impaired gene expression and toxic protein aggregation.
- Inflammatory and autoimmune diseases – driven by immune cells with abnormal epigenetic signatures.
Targeting a Window of Opportunity: Reversible Mechanisms
A defining advantage of epigenetic and epiproteomic alterations? They’re reversible. This makes them high attractive drug targets.
Emerging therapeutics—such as epigenetic inhibitors—can restore proper regulation of gene expression and protein function. This strategy goes beyond symptom control, aiming to correct disease mechanisms at their source. It paves the way for:
- Precision medicine approaches.
- Innovative small molecule drug classes.
- Disease-modifying therapies across high-impact medical areas.
HDAC6: A High-Impact Target at the Intersection of Epigenetics and Epiproteomics
Histone Deacetylase 6 (HDAC6) represents a unique therapeutic target that bridges epigenetics and epiproteomics. Unlike most HDACs, that primarily act in the nucleus to regulate chromatin structure, HDAC6 operates in the cytoplasm, modulating a wide range of non-histone proteins through post-translational deacetylation.
This places HDAC6 squarely within the domain of epiproteomics—the dynamic landscape of protein modifications that govern cellular behavior in health and disease.
The Functional Power of HDAC6
HDAC6 influences multiple cellular processes by controlling protein acetylation, including:
- Protein degradation pathways, such as autophagy and aggresome formation.
- Intracellular transport, through modulation of microtubule-dependent trafficking.
- Cytoskeletal architecture and motility.
- Cellular stress and immune signaling.
These pathways are often disrupted in disease and are increasingly recognized as central to pathology in both cancer and chronic inflammatory conditions.
Therapeutic Relevance Across Major Indications
Abnormal HDAC6 activity has been associated with:
- Cancer – HDAC6 supports tumor survival, immune evasion, and stress adaptation.
Obesity — linked to metabolic inflammation and impaired leptin signaling, leading to dysregulated energy homeostasis and weight control.
- Neurodegenerative disorders – such as ALS, Alzheimer’s, and Parkinson’s, where HDAC6 impacts protein aggregation and axonal transport.
- Autoimmune and inflammatory diseases – through modulation of immune cell signaling and cytokine release
Crucially, HDAC6 inhibition can modulate these disease-relevant pathways without disrupting core epigenetic programming, enabling a selective and low-toxicity therapeutic approach.
- Autoimmune and inflammatory diseases – through modulation of immune cell signaling and cytokine release
At Quimatryx, we are pioneering a pipeline of next-generation, highly selective HDAC6 inhibitors designed to unlock safer and more precise treatments for oncology, obesity, neurology, and inflammation.
By targeting the reversible regulators of gene and protein function, we aim to reshape the future of epigenetic and epiproteomic medicine, bringing transformative therapies to patients in areas of greatest need.